Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PSA Prostate Cancer Screening Does More Harm Than Good, USPSTF Concludes

This article was originally published in The Gray Sheet

Executive Summary

The final recommendations are a major shift in policy for the commonly performed blood test, and one certain to face ongoing controversy.

You may also be interested in...



CMS Issues List Of Potential National Coverage Determination Topics

Most of the 33 items or services in the list have implications for manufacturers of medical devices, combination products or diagnostics.

Capitol Hill In Brief

Prostate Cancer Detection Research and Education Act introduced in House and Senate. Safe Doses Act, to increase fines for medical product thefts and counterfeiting, passes House. More Capitol Hill briefs.

New Products In Brief

Recent market launches and clearances include Glaukos’ iStent for glaucoma, Beckman Coulter’s Prostate Health Index blood test for prostate cancer and Siemens’ Sysmex CA-600 Systems for lab hemostasis testing.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT031258

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel